Kriya Therapeutics secured $313 million in a new funding round, making it one of the largest private biotech fundraises this year. The company develops gene therapies across neurology, metabolic health, and ophthalmology, with two candidates in clinical development. Recent acquisitions of Redpin Therapeutics and Tramontane Therapeutics broadened its pipeline. CEO Shankar Ramaswamy emphasized Kriya's integrated approach addressing industry-wide gene therapy challenges to bring treatments for prevalent diseases to mainstream medicine.